🇺🇸 JNJ-63723283 in United States

13 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 23 April 2025 – 23 April 2026
• Total reports: 13

Most-reported reactions

1. Neutropenia — 2 reports (15.38%)
2. Platelet Count Decreased — 2 reports (15.38%)
3. Rash Maculo-Papular — 2 reports (15.38%)
4. Anaemia — 1 report (7.69%)
5. Cataract — 1 report (7.69%)
6. Dehydration — 1 report (7.69%)
7. Diabetic Ketoacidosis — 1 report (7.69%)
8. Diarrhoea — 1 report (7.69%)
9. Embolism — 1 report (7.69%)
10. Epididymitis — 1 report (7.69%)

Source database →

Frequently asked questions

Is JNJ-63723283 approved in United States?

JNJ-63723283 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for JNJ-63723283 in United States?

Janssen Research & Development, LLC is the originator. The local marketing authorisation holder may differ — check the official source linked above.